The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 13, 2024

Filed:

Jul. 27, 2018
Applicant:

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

Nataly Manjarrez Orduño, Princeton, NJ (US);

Suzanne J. Suchard, Portland, OR (US);

Assignee:

Bristol-Myers Squibb Company, Princeton, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01); G01N 33/569 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57484 (2013.01); A61K 45/06 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 2039/507 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present disclosure relates to the finding that the ratio of circulating (i.e., peripheral blood) central memory T cells to circulating effector T cells in a cancer patient can predict whether a tumor has an inflammatory milieu or not. In addition, since having an inflammatory milieu ('hot tumor') is a positive factor for responding to checkpoint inhibitors, e.g., PD-1 antagonists, this assay on peripheral blood can also be used to predict a response to a checkpoint inhibitor, e.g., an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or an antibody or an antigen binding portion thereof that binds specifically to PD-1 ligand 1 (PD-L1) and inhibits PD-L1 activity.


Find Patent Forward Citations

Loading…